TechneLite Technetium Tc99m Generator

Mo-99 and Tc-99m: Critical to Nuclear Medicine

Molybdenum-99 (Mo-99) is the parent isotope of technetium-99m (Tc-99m), which is the radioisotope most widely utilized for nuclear medicine diagnostic imaging tests.

What is TechneLite®?

TechneLite® is a technetium-99m (Tc-99m) generator that provides the essential medical isotope used by hospitals and radiopharmacies to radiolabel Cardiolite® (Kit for the Preparation of Technetium Tc-99m Sestamibi for Injection) and other radiopharmaceuticals requiring Tc-99m used in nuclear medicine imaging procedures.

Learn More

TechneLite® Tc 99m Generator Supply Update

November 2022 - We would like to provide you with an update on the European reactor outage, the associated Moly supply disruptions, and the impact on our Xenon-133 production.

According to a memo on November 18 from Nuclear Medicine Europe, the Belgian reactor BR2 has cancelled its November cycle entirely. The Czech reactor LVR15 did successfully restart on November 18, and HFR in the Netherlands is expected to restart soon. Based on this information, Nuclear Medicine Europe has projected Moly shortages to continue through the fourth week of November. As has been the case throughout this period of reactor schedule changes, Lantheus remains fully capable of supplying our regular standing orders thanks to our globally diversified and balanced Moly supply chain. Further, we continue to work closely with our suppliers to increase production capacity for additional orders from our customers.

Regarding our Xenon-133, which is sourced solely from European reactors, we will not have a production run this Wednesday, November 23 and next Wednesday, November 30. We will return to normal production on Wednesday, December 7. Given the successful restart of LVR15, we have high confidence in this return date.

Please stay in touch with your Lantheus Nuclear Medicine Sales Representative for the latest information on additional TechneLite and Xenon‐133 availability. We believe our actions may alleviate some of the impact of this disruption to you, your operations, and the patients we all serve.

As this situation evolves, we will continue to provide additional information. Should you have any questions or need additional information, please contact your Lantheus Nuclear Medicine Sales Representative or Lantheus Customer Service at 1‐800‐299‐3431.


Lantheus Circles the Globe to Bring TechneLite® to YouLantheus Circles the Globe to Bring TechneLite to You

As a leader in the radiopharmaceutical business, Lantheus has developed a world class, globally diversified and balanced Molybdenum-99 (Mo-99) supply chain for the procurement of Mo-99. The company presently receives Mo-99 from three of the four major Mo-99 processors and five of the six associated producing reactors.

TechneLite Production Process Map


The TechneLite® generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. 

Sodium Pertechnetate Tc 99m Injection is used IN ADULTS as an agent for:
Thyroid Imaging
Salivary Gland Imaging
Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.
Nasolacrimal Drainage System Imaging

Sodium Pertechnetate Tc 99m Injection is used IN CHILDREN as an agent for:
Thyroid Imaging
Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.


None Known.

Important Safety Information:

Allergic reactions including anaphylaxis have been reported infrequently following the administration of Sodium Pertechnetate Tc 99m Injection.


Radiation risks associated with the use of Sodium Pertechnetate Tc 99m Injection are greater in children than in adults and, in general, the younger the child, the greater the risk owing to greater absorbed radiation doses and longer life expectancy.
These greater risks should be taken firmly into account in all benefit-risk assessments involving children.  Long-term cumulative radiation exposure may be associated with an increased risk of cancer.


Since the eluate does not contain an antimicrobial agent, it should not be used after 12 hours from the time of TechneLite®, Technetium Tc 99m Generator, elution. After the termination of the nasolacrimal imaging procedure, blowing the nose and washing the eyes with sterile distilled water or an isotonic sodium chloride solution will further minimize the radiation dose. As in the use of any radioactive material, care should be taken to minimize radiation exposure to patients and occupational workers. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience and who are licensed in the safe handling of radionuclides.

Please see full Prescribing Information

To place an order call 1-800-299-3431 or visit